T-cell gene therapy-based strategies have the potential to improve current hematopoietic cell transplantation (HCT) treatment with improved control of graft-versushost disease. [1] [2] [3] However, selection of a pure population of gene-modified T cells, the efficient elimination of transduced cells if needed and the prevention of transgene immunogenicity remain crucial problems that have not been completely addressed. One potential approach to improve gene therapy applications in humans is to develop more effective in vivo selection of gene-modified cells. The insertion of a drug-resistance gene that gave a proliferative advantage to the genemodified cells with drug selection would enrich for transduced cells in vivo. The ideal selection method would be highly effective yet have minimal toxicity. Recently, Yam et al. 4 reported on the transduction of target cells with a mycophenolate mofetil (MMF) resistance gene, a variant of inosine monophosphate dehydrogenase 2 (IMPDH2). The gene IMPDH IY was generated by inserting two-point mutations in the wildtype human IMPDH2: a C to T transition at base 998 relative to initiation of translation, altering threonine-333 to isoleucine, and a C to A transversion at base 1052, altering serine-351 to tyrosine. The trans-dominant IMPDH IY gene could permit the in vivo selection of transduced cells with MMF. Wild-type IMPDH2 is the rate-limiting enzyme in de novo purine biosynthesis. It is preferentially expressed in activated T and B cells, and Tcell proliferation is dependent on its activity. Mycophenolic acid, the active metabolite of MMF, uncompetitively inhibits IMPDH2, thus blocking de novo purine synthesis. 5, 6 Several mutations of IMPDH2 have been studied including T333I, which generates a 10 000-fold increased resistance to mycophenolic acid in murine neuroblastoma cells without the loss of de novo purine biosynthesis activity. 7, 8 Furthermore, to improve the safety of gene therapy, it is helpful to eliminate transduced cells if their activity is not needed. The inducible suicide gene herpes simplex virus-1 thymidine kinase (HSV-TK) has been used to control cell survival by permitting killing of transduced cells with the prodrug ganciclovir.
2,3,9 HSV-TK-transduced donor lymphocytes have been studied in patients after allogeneic HCT. 1 Following allogeneic HCT, donor T cells facilitate engraftment and induce graft-versustumor effects, but alloreactive donor T cells can also cause fatal graft-versus-host disease. 10 Gene modification of donor T cells with HSV-TK renders alloreactive T cells sensitive to ablation with ganciclovir. This approach may improve the safety of allogeneic HCT by permitting control of the graft-versus-host reaction. 1, 2, 11 The DCD34/HSV-TK75 chimeric suicide gene consisting of the extracellular and transmembrane domains of human CD34 fused in-frame with full-length HSV-TK (DCD34/ TK) was developed to ensure expression of HSV-TK in all selected cells with rapid and efficient isolation of gene-modified cells using clinically approved CD34 selection techniques. 12 We sought to combine the in vivo selection potential of MMF resistance provided by IMPDH IY with the inducible suicide gene DCD34/TK in one vector. We studied the in vitro function of a bicistronic lentiviral vector (LV) that rendered transduced cells both resistant to the anti-metabolite immunosuppressive drug MMF and sensitive to ganciclovir. We hypothesized that after in vivo infusion of transduced T cells that were MMF-resistant and ganciclovir-sensitive, administration of MMF would favor the proliferation of DCD34/TK cells over non-transduced cells and could also potentially suppress immune responses against the vector transgenes. Administration of ganciclovir would allow for rapid and specific ablation of transduced cells if needed.
We cloned and evaluated the function of three LVs encoding IMPDH IY the chimeric suicide gene DCD34/ TK, and the combination of DCD34/TK and IMPDH IY , respectively ( Figure 1 ). All vectors used in this study were pseudotyped with the chimeric protein RD114/TR, encoding the RD114 virus envelope glycoprotein, and the MLV-A cytoplasmic tail (designated TR). 13 In preparation for in vivo experiments in the well-established dog model, the RD114/TR pseudotype improved the efficiency and the stability of freshly isolated canine T-cell transduction when compared to the VSV-G pseudotype (data not shown). . LV stocks were prepared by transient calcium transfection of human 293T cells as described. 23, 24 The construct pCMVR8.74 was used as the packaging vector. Construct phCMV-RD114/TR, 13 encoding for the chimeric protein RD114 virus envelope glycoprotein, and the MLV-A cytoplasmic tail (designated TR), were used as the pseudotyping vector. CMV, cytomegalovirus; CPPT, central polypurine tract; GFP, green fluorescence protein; HIV, human immunodeficiency virus; hPGK, human phosphoglycerate kinase promoter; IMPDH, inosine monophosphate dehydrogenase; IRES, internal ribosome entry site; LTR, long-terminal repeat; LV, lentiviral vectors; MLV, murine leukemia virus; MSCV, murine stem cell virus; RRE, Rev-response element; SIN, self-inactivating; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. One of the challenges of gene therapy is to provide transduced cells with a selective proliferative advantage over non-transduced cells. This is particularly important when transduction efficiency is too low for therapeutic effect or if the gene-modified cells do not have an immediate functional therapeutic advantage over nontransduced cells. An advantage of MMF as an in vivo selection drug is the potential for less toxicity compared to other in vivo selection drugs such as methotrexate resistance with dihydrofolate reductase variants 14 or bischloroethyl nitrosourea resistance with methyl-guanine methyltransferase variants. 15, 16 Another major obstacle for gene therapy applications in humans is the likelihood of development of host immune responses to the novel transgene-encoded proteins. 17, 18 Strategies to prevent or control immune responses toward transgene-encoded proteins are needed to allow for clinical translation of promising gene therapy approaches. We suggest that administration of MMF following the infusion of IMPDH IY -transduced lymphocytes would not only favor the proliferation of the transduced cells but could also substantially inhibit transgene immunogenicity. The potential benefit of the IMPDH IY gene remains to be evaluated in vivo.
The use of the IMPDH IY gene that confers resistance to MMF was initially reported by Yam et al. 4 They hypothesized that an in vivo lymphocyte or CD34 hematopoietic progenitor cell selection system might be applicable in human immunodeficiency virus gene therapy to enrich for gene-modified T cells. We extended their studies by combining IMPDH IY with an inducible suicide gene and a selection marker, DCD34/TK, in a single LV.
The current data support a gene therapy strategy that may be particularly useful in allogeneic HCT. Following We have previously evaluated HSV-TK-transduced T cells in the well-established preclinical dog model of allogeneic HCT. 19 Furthermore, we showed that genemodified cytotoxic T lymphocytes maintained in vivo function in this model. 20 However, immune responses against the HSV-TK gene and selection markers are a known risk, 21 and the likelihood of transgene-specific immune responses increases with reduced-intensity conditioning regimens. After allogeneic HCT and infusion of IMPDH IY -transduced donor T cells, MMF administration would not affect the graft-versus-host function of transduced donor lymphocytes. One transplant setting in which MMF-resistant donor T cells would be particularly useful is following T-cell-depleted HLAhaploidentical HCT. With MMF treatment, the add-back of transduced T cells would maintain their alloreactive function and the ability to facilitate engraftment. MMF treatment would suppress the host-versus-graft response, and thus help prevent graft rejection and immune responses against the transgene-encoded proteins. Because post-grafting immunosuppression with MMF would reduce the risk of graft rejection, this approach could also permit a decrease in the intensity of the total body irradiation and chemotherapy conditioning regimen needed to establish donor engraftment. Once engraftment was established, ganciclovir would selectively kill alloreactive-transduced donor T cells if graft-versus-host disease occurred.
In summary, the LV-DCD34/TK.IMPDH IY conferred a strong proliferative advantage to transduced K562 cells that were otherwise inhibited with MMF. Cells transduced with the IMPDH IY vectors showed robust proliferation with MMF concentrations ranging from 0.1 to 5 mM, which are drug concentrations that are routinely achieved in clinical use of MMF. 22 The transgeneencoded cell surface expression of DCD34 permitted efficient immunomagnetic selection of transduced cells. With the cytoplasmic domain deleted, DCD34 is a potentially ideal clinical marker for transduced cells, given that CD34 immunoselection protocols are well established and readily available, facilitating future applications of this vector in preclinical and clinical models. The bifunctional DCD34/TK molecule provided ganciclovir sensitivity as shown by Rettig et al. 12 previously.
We have demonstrated proof-of-principle that an MMF-resistance gene therapy approach can be combined with an inducible suicide gene and a selectable marker in a single LV. The K562 cell line allowed for stable experimental conditions for an extended duration of data collection. The data from primary T lymphocytes indicate that MMF resistance is a selectable phenotype. In vivo animal data with transduced T cells are necessary to validate our strategy. We aim to evaluate the applicability of this approach using the well-established canine model of HCT.
